Evidence map›Paper›PMID 39525948›Full record

ArticlePulmonary circulation2024

Delta-like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials.

Casandra E Besse, Nolan M Winicki, Cristian Puerta, Moises Hernandez, Jason X-J Yuan, Patricia A Thistlethwaite

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Casandra E BesseDivision of Cardiothoracic Surgery University of California San Diego California USA.ORCID 0009-0007-4171-1908
Nolan M WinickiDivision of Cardiothoracic Surgery University of California San Diego California USA.ORCID https://orcid.org/0000-0002-0784-2679
Cristian PuertaDivision of Cardiothoracic Surgery University of California San Diego California USA.ORCID 0000-0002-0953-0150
Moises HernandezDivision of Cardiothoracic Surgery University of California San Diego California USA.ORCID https://orcid.org/0000-0002-7651-2673
Jason X-J YuanUniversity of Florida Scripps Institute for Biomedical Innovation and Technology Jupiter Florida USA.ORCID https://orcid.org/0000-0002-0685-4862
Patricia A ThistlethwaiteDivision of Cardiothoracic Surgery University of California San Diego California USA.ORCID 0000-0002-1986-7304

Funding

NOTCH3 ECD as a Serum Biomarker for Pulmonary Arterial HypertensionR01HL169861 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PATRICIA A THISTLETHWAITE · 2024 to 2026
$1.8M
NHLBI NIH HHS R01 HL169861
6 · The paper itself

Abstract

Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.

Indexed as

adverse effectsclinical trialspulmonary hypertension

Identifiers

PMID39525948
PMCPMC11544561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.